{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:25:25Z","timestamp":1777519525764,"version":"3.51.4"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.phrs.2020.105050","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T13:11:57Z","timestamp":1593177117000},"page":"105050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Controlling leukocyte trafficking in IBD"],"prefix":"10.1016","volume":"159","author":[{"given":"Marisol","family":"Veny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7513-0764","authenticated-orcid":false,"given":"Agn\u00e8s","family":"Fern\u00e1ndez-Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juli\u00e1n","family":"Pan\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.105050_bib0005","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjz206","article-title":"Molecular structure and function of Janus kinases: implications for the development of inhibitors","author":"Garrido-Trigo","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"Suppl._2","key":"10.1016\/j.phrs.2020.105050_bib0010","doi-asserted-by":"crossref","first-page":"S633","DOI":"10.1093\/ecco-jcc\/jjy011","article-title":"Past, present and future of therapeutic interventions targeting leukocyte trafficking in inflammatory bowel disease","volume":"12","author":"Pan\u00e9s","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"11","key":"10.1016\/j.phrs.2020.105050_bib0015","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nri3298","article-title":"HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes","volume":"12","author":"Girard","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105050_bib0020","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.gastro.2015.10.046","article-title":"Leukocyte trafficking to the small intestine and Colon","volume":"150","author":"Habtezion","year":"2016","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.phrs.2020.105050_bib0025","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nri2156","article-title":"Getting to the site of inflammation: the leukocyte adhesion cascade updated","volume":"7","author":"Ley","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.phrs.2020.105050_bib0030","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2174\/156652409789105525","article-title":"Role of beta7 integrins in intestinal lymphocyte homing and retention","volume":"9","author":"Gorfu","year":"2009","journal-title":"Curr. Mol. Med."},{"issue":"5","key":"10.1016\/j.phrs.2020.105050_bib0035","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.immuni.2014.10.008","article-title":"Leukocyte migration into inflamed tissues","volume":"41","author":"Nourshargh","year":"2014","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.phrs.2020.105050_bib0040","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00441-014-1809-9","article-title":"Leukocyte recruitment in inflammation: basic concepts and new mechanistic insights based on new models and microscopic imaging technologies","volume":"355","author":"Leick","year":"2014","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.phrs.2020.105050_bib0045","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaut.2016.01.001","article-title":"Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity","volume":"68","author":"Trivedi","year":"2016","journal-title":"J. Autoimmun."},{"issue":"11","key":"10.1016\/j.phrs.2020.105050_bib0050","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1002\/1521-4141(200211)32:11<3197::AID-IMMU3197>3.0.CO;2-1","article-title":"Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival","volume":"32","author":"Sasaki","year":"2002","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.phrs.2020.105050_bib0055","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1440-1827.2007.02117.x","article-title":"Blockade of interferon-gamma-inducible protein-10 attenuates chronic experimental colitis by blocking cellular trafficking and protecting intestinal epithelial cells","volume":"57","author":"Suzuki","year":"2007","journal-title":"Pathol. Int."},{"issue":"7","key":"10.1016\/j.phrs.2020.105050_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101622","article-title":"The role of CXCR3 in DSS-induced colitis","volume":"9","author":"Chami","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.phrs.2020.105050_bib0065","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.4049\/jimmunol.171.3.1401","article-title":"Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10-\/- mice","volume":"171","author":"Singh","year":"2003","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.phrs.2020.105050_bib0070","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/01.MIB.0000178263.34099.89","article-title":"Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice","volume":"11","author":"Hyun","year":"2005","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.phrs.2020.105050_bib0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0002-9440(10)65128-0","article-title":"Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis","volume":"155","author":"Uguccioni","year":"1999","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105050_bib0080","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ibd.23034","article-title":"Enhanced expression of CXCL10 in inflammatory bowel disease: potential role of mucosal Toll-like receptor 3 stimulation","volume":"19","author":"Ostvik","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"issue":"5","key":"10.1016\/j.phrs.2020.105050_bib0085","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/mi.2015.132","article-title":"IL-10 downregulates CXCR3 expression on Th1 cells and interferes with their migration to intestinal inflammatory sites","volume":"9","author":"Wadwa","year":"2016","journal-title":"Mucosal Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2020.105050_bib0090","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/gast.2001.20904","article-title":"Characterization of epithelial chemoattractants for human intestinal intraepithelial lymphocytes","volume":"120","author":"Shibahara","year":"2001","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.phrs.2020.105050_bib0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/gast.2001.20914","article-title":"Regulated production of interferon-inducible T-cell chemoattractants by human intestinal epithelial cells","volume":"120","author":"Dwinell","year":"2001","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.phrs.2020.105050_bib0100","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/jlb.65.5.691","article-title":"Assessment of chemokine receptor expression by human Th1 and Th2 cells in vitro and in vivo","volume":"65","author":"Annunziato","year":"1999","journal-title":"J. Leukoc. Biol."},{"issue":"5","key":"10.1016\/j.phrs.2020.105050_bib0105","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","article-title":"CXCR3 in T cell function","volume":"317","author":"Groom","year":"2011","journal-title":"Exp. Cell Res."},{"issue":"5","key":"10.1016\/j.phrs.2020.105050_bib0110","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1189\/jlb.5A0717-302","article-title":"A novel function of CXCL10 in mediating monocyte production of proinflammatory cytokines","volume":"102","author":"Zhao","year":"2017","journal-title":"J. Leukoc. Biol."},{"issue":"12","key":"10.1016\/j.phrs.2020.105050_bib0115","doi-asserted-by":"crossref","first-page":"8391","DOI":"10.4049\/jimmunol.181.12.8391","article-title":"CCR6 regulates the migration of inflammatory and regulatory T cells","volume":"181","author":"Yamazaki","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2020.105050_bib0120","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1023\/B:JOCI.0000018066.46279.6b","article-title":"Increased expression of CCL20 in human inflammatory bowel disease","volume":"24","author":"Kaser","year":"2004","journal-title":"J. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2020.105050_bib0125","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/jlb.65.3.349","article-title":"Expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in acute and chronic inflammation","volume":"65","author":"Connor","year":"1999","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2020.105050_bib0130","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2020.105050_bib0135","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.immuni.2004.08.011","article-title":"Retinoic acid imprints gut-homing specificity on T cells","volume":"21","author":"Iwata","year":"2004","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.phrs.2020.105050_bib0140","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.immuni.2004.10.002","article-title":"Retinoic acid: an educational \"vitamin elixir\" for gut-seeking T cells","volume":"21","author":"Mora","year":"2004","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.phrs.2020.105050_bib0145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(93)90305-A","article-title":"Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1","volume":"74","author":"Berlin","year":"1993","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.phrs.2020.105050_bib0150","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.it.2007.01.007","article-title":"Tipping the gatekeeper: S1P regulation of endothelial barrier function","volume":"28","author":"Rosen","year":"2007","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2020.105050_bib0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/ATVBAHA.110.213496","article-title":"Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis","volume":"31","author":"Skoura","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2020.105050_bib0160","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/CIRCRESAHA.110.235028","article-title":"Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte\/macrophages in inflammation and atherosclerosis","volume":"108","author":"Keul","year":"2011","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2020.105050_bib0165","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev-immunol-020711-075011","article-title":"Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs","volume":"30","author":"Cyster","year":"2012","journal-title":"Annu. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.phrs.2020.105050_bib0170","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrneurol.2010.76","article-title":"Fingolimod is a potential novel therapy for multiple sclerosis","volume":"6","author":"Aktas","year":"2010","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.phrs.2020.105050_bib0175","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.4049\/jimmunol.178.4.2458","article-title":"FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells","volume":"178","author":"Daniel","year":"2007","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.phrs.2020.105050_bib0180","first-page":"699","article-title":"The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice","volume":"16","author":"Deguchi","year":"2006","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2020.105050_bib0185","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/mi.2016.35","article-title":"Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease","volume":"10","author":"Karuppuchamy","year":"2016","journal-title":"Mucosal Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105050_bib0190","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ibd\/izz174","article-title":"Sphingosine-1-phosphate lyase inhibition alters the S1P gradient and ameliorates Crohn\u2019s-Like ileitis by suppressing thymocyte maturation","volume":"26","author":"Karuppuchamy","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"issue":"7","key":"10.1016\/j.phrs.2020.105050_bib0195","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/ni1083","article-title":"Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone","volume":"5","author":"Cinamon","year":"2004","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105050_bib0200","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1189\/jlb.0904487","article-title":"Sphingosine 1-phosphate receptor agonist FTY720-phosphate causes marginal zone B cell displacement","volume":"78","author":"Vora","year":"2005","journal-title":"J. Leukoc. Biol."},{"issue":"4","key":"10.1016\/j.phrs.2020.105050_bib0205","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.2353\/ajpath.2010.100119","article-title":"FTY720 regulates bone marrow egress of eosinophils and modulates late-phase skin reaction in mice","volume":"177","author":"Sugita","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"11","key":"10.1016\/j.phrs.2020.105050_bib0210","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1084\/jem.20090525","article-title":"T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow","volume":"206","author":"Jenne","year":"2009","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.phrs.2020.105050_bib0215","doi-asserted-by":"crossref","first-page":"7973","DOI":"10.4049\/jimmunol.175.12.7973","article-title":"The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+\/CD25+ T-regulatory cells and enhances their functional activity","volume":"175","author":"Sawicka","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2020.105050_bib0220","doi-asserted-by":"crossref","first-page":"109","DOI":"10.12703\/P6-109","article-title":"S1P signaling: new therapies and opportunities","volume":"6","author":"Gonzalez-Cabrera","year":"2014","journal-title":"F1000Prime Rep."},{"issue":"1","key":"10.1016\/j.phrs.2020.105050_bib0225","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1083\/jcb.140.1.197","article-title":"Direct and regulated interaction of integrin alphaEbeta7 with E-cadherin","volume":"140","author":"Higgins","year":"1998","journal-title":"J. Cell Biol."},{"issue":"6502","key":"10.1016\/j.phrs.2020.105050_bib0230","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/372190a0","article-title":"Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin","volume":"372","author":"Cepek","year":"1994","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2020.105050_bib0235","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1365-2567.1996.d01-727.x","article-title":"Distribution of beta 7 integrins in human intestinal mucosa and organized gut-associated lymphoid tissue","volume":"89","author":"Farstad","year":"1996","journal-title":"Immunology"},{"issue":"10","key":"10.1016\/j.phrs.2020.105050_bib0240","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1002\/eji.1830211041","article-title":"Expression and regulation of beta 7(beta p) integrins on mouse lymphocytes: relevance to the mucosal immune system","volume":"21","author":"Kilshaw","year":"1991","journal-title":"Eur. J. Immunol."},{"issue":"12","key":"10.1016\/j.phrs.2020.105050_bib0245","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.4049\/jimmunol.158.12.5584","article-title":"Specialization of mucosal follicular dendritic cells revealed by mucosal addressin-cell adhesion molecule-1 display","volume":"158","author":"Szabo","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2020.105050_bib0250","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1600-065X.2007.00540.x","article-title":"The role of integrins and coreceptors in refining thresholds for B-cell responses","volume":"218","author":"Batista","year":"2007","journal-title":"Immunol. Rev."},{"issue":"11","key":"10.1016\/j.phrs.2020.105050_bib0255","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1002\/(SICI)1521-4141(199811)28:11<3605::AID-IMMU3605>3.0.CO;2-J","article-title":"MAdCAM-1 costimulates T cell proliferation exclusively through integrin alpha4beta7, whereas VCAM-1 and CS-1 peptide use alpha4beta1: evidence for \u201cremote\u201d costimulation and induction of hyperresponsiveness to B7 molecules","volume":"28","author":"Lehnert","year":"1998","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.phrs.2020.105050_bib0260","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3109\/15419069409014217","article-title":"Integrin alpha 4 beta 7 co-stimulation of human peripheral blood T cell proliferation","volume":"2","author":"Teague","year":"1994","journal-title":"Cell Adhes. Commun."},{"issue":"6","key":"10.1016\/j.phrs.2020.105050_bib0265","doi-asserted-by":"crossref","first-page":"842","DOI":"10.4161\/mabs.26392","article-title":"In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes","volume":"5","author":"Wyant","year":"2013","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/j.phrs.2020.105050_bib0270","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/s41385-018-0044-1","article-title":"MAdCAM costimulation through Integrin-alpha4beta7 promotes HIV replication","volume":"11","author":"Nawaz","year":"2018","journal-title":"Mucosal Immunol."},{"issue":"9","key":"10.1016\/j.phrs.2020.105050_bib0275","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1182\/blood.V98.9.2626","article-title":"Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T- and B-cell development and a reduction in T-cell receptor \u03b3\u03b4+ gut intraepithelial lymphocytes","volume":"98","author":"Wurbel","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.phrs.2020.105050_bib0280","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2005-07-2860","article-title":"Gut-associated lymphoid tissue-primed CD4+ T cells display CCR9-dependent and -independent homing to the small intestine","volume":"107","author":"Stenstad","year":"2006","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.phrs.2020.105050_bib0285","doi-asserted-by":"crossref","first-page":"10122","DOI":"10.1073\/pnas.0700269104","article-title":"Differential homing mechanisms regulate regionalized effector CD8alphabeta+ T cell accumulation within the small intestine","volume":"104","author":"Stenstad","year":"2007","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"7","key":"10.1016\/j.phrs.2020.105050_bib0290","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1053\/j.gastro.2008.02.085","article-title":"Role of beta7 integrin and the chemokine\/chemokine receptor pair CCL25\/CCR9 in modeled TNF-dependent Crohn\u2019s disease","volume":"134","author":"Apostolaki","year":"2008","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.phrs.2020.105050_bib0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060094","article-title":"Prospective randomized oral-therapy evaluation in Crohn\u2019s disease trial P-SG. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn\u2019s disease","volume":"8","author":"Keshav","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.phrs.2020.105050_bib0300","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/apt.13398","article-title":"Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn\u2019s disease","volume":"42","author":"Feagan","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2020.105050_bib0305","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/ecco-jcc\/jjv224","article-title":"Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: a randomised, placebo-controlled, phase 2b study","volume":"10","author":"Sandborn","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"9","key":"10.1016\/j.phrs.2020.105050_bib0310","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1111\/bcp.13286","article-title":"CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6(+) cells in an experimental suction blister","volume":"83","author":"Bouma","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2020.105050_bib0315","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.phrs.2020.105050_bib0320","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.phrs.2020.105050_bib0325","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1136\/gutjnl-2015-310022","article-title":"Differential effects of alpha4beta7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo","volume":"65","author":"Fischer","year":"2016","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.phrs.2020.105050_bib0330","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/gutjnl-2018-316023","article-title":"Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease","volume":"68","author":"Zeissig","year":"2019","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.phrs.2020.105050_bib0335","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-3083.1995.tb03709.x","article-title":"Human intestinal B-cell blasts and plasma cells express the mucosal homing receptor integrin alpha 4 beta 7","volume":"42","author":"Farstad","year":"1995","journal-title":"Scand. J. Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2020.105050_bib0340","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/mi.2016.59","article-title":"The human intestinal B-cell response","volume":"9","author":"Spencer","year":"2016","journal-title":"Mucosal Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105050_bib0345","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clim.2012.05.008","article-title":"Wagner N. beta7 integrin controls immunogenic and tolerogenic mucosal B cell responses","volume":"144","author":"Schippers","year":"2012","journal-title":"Clin. Immunol."},{"issue":"461","key":"10.1016\/j.phrs.2020.105050_bib0350","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau4711","article-title":"Anti-alpha4beta7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals","volume":"10","author":"Uzzan","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.phrs.2020.105050_bib0355","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1053\/j.gastro.2018.11.035","article-title":"Efficacy and safety of abrilumab in a randomized, placebo-controlled trial for moderate-to-severe ulcerative colitis","volume":"156","author":"Sandborn","year":"2019","journal-title":"Gastroenterology"},{"issue":"Suppl._1","key":"10.1016\/j.phrs.2020.105050_bib0360","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1093\/ecco-jcc\/jjx002.034","article-title":"OP035 Efficacy and safety of abrilumab (AMG 181\/MEDI 7183) therapy for moderate to severe Crohn\u2019s disease","volume":"11","author":"Sandborn","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"9940","key":"10.1016\/j.phrs.2020.105050_bib0365","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"issue":"39","key":"10.1016\/j.phrs.2020.105050_bib0370","article-title":"Cellular mechanisms of etrolizumab treatment in inflammatory bowel disease","volume":"10","author":"Lichnog","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2020.105050_bib0375","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.4049\/jimmunol.162.8.4975","article-title":"Administration of mAb against alpha E beta 7 prevents and ameliorates immunization-induced colitis in IL-2-\/- mice","volume":"162","author":"Ludviksson","year":"1999","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2020.105050_bib0380","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41590-018-0298-5","article-title":"Hobit- and Blimp-1-driven CD4(+) tissue-resident memory T cells control chronic intestinal inflammation","volume":"20","author":"Zundler","year":"2019","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2020.105050_bib0385","first-page":"610","article-title":"alphaEbeta7 integrin identifies subsets of pro-inflammatory colonic CD4+ t lymphocytes in ulcerative colitis","volume":"11","author":"Lamb","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"2","key":"10.1016\/j.phrs.2020.105050_bib0390","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2015.10.041","article-title":"Association between response to Etrolizumab and expression of integrin alphaE and granzyme a in Colon biopsies of patients with ulcerative colitis","volume":"150","author":"Tew","year":"2016","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1016\/j.phrs.2020.105050_bib0395","doi-asserted-by":"crossref","first-page":"13031","DOI":"10.1073\/pnas.192162899","article-title":"Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells","volume":"99","author":"Lehmann","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.phrs.2020.105050_bib0400","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1084\/jem.20040662","article-title":"Essential role for CD103 in the T cell-mediated regulation of experimental colitis","volume":"202","author":"Annacker","year":"2005","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.phrs.2020.105050_bib0405","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.4049\/jimmunol.180.4.2573","article-title":"A CD8+\/CD103high T cell subset regulates TNF-mediated chronic murine ileitis","volume":"180","author":"Ho","year":"2008","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.phrs.2020.105050_bib0410","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/ecco-jcc\/jjx160","article-title":"Intestinal T cell profiling in inflammatory bowel disease: linking T cell subsets to disease activity and disease Course","volume":"12","author":"Smids","year":"2018","journal-title":"J. Crohns Colitis"},{"issue":"9","key":"10.1016\/j.phrs.2020.105050_bib0415","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/ibd\/izz049","article-title":"Intestinal CD103+CD4+ and CD103+CD8+ T-cell subsets in the gut of inflammatory bowel disease patients at diagnosis and during follow-up","volume":"25","author":"Roosenboom","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"issue":"18","key":"10.1016\/j.phrs.2020.105050_bib0420","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn\u2019s disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2020.105050_bib0425","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn\u2019s disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.phrs.2020.105050_bib0430","first-page":"189","article-title":"Natalizumab in Crohn\u2019s disease: past and future areas of applicability","volume":"26","author":"Armuzzi","year":"2013","journal-title":"Ann. Gastroenterol."},{"issue":"11","key":"10.1016\/j.phrs.2020.105050_bib0435","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1016\/j.crohns.2013.03.014","article-title":"Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice","volume":"7","author":"Sugiura","year":"2013","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"7","key":"10.1016\/j.phrs.2020.105050_bib0440","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1053\/j.gastro.2015.08.044","article-title":"Safety and efficacy of AJM300, an oral antagonist of alpha4 integrin, in induction therapy for patients with active ulcerative colitis","volume":"149","author":"Yoshimura","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.phrs.2020.105050_bib0445","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.phrs.2020.105050_bib0450","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1053\/gast.2001.27968","article-title":"Immune cell trafficking in uterus and early life is dominated by the mucosal addressin MAdCAM-1 in humans","volume":"121","author":"Salmi","year":"2001","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.phrs.2020.105050_bib0455","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nri1784","article-title":"Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease","volume":"6","author":"Adams","year":"2006","journal-title":"Nat. Rev. Immunol."},{"issue":"10090","key":"10.1016\/j.phrs.2020.105050_bib0460","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(17)30930-3","article-title":"Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"390","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.phrs.2020.105050_bib0465","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1136\/gutjnl-2016-313457","article-title":"Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn\u2019s disease: report of the OPERA study","volume":"67","author":"Sandborn","year":"2018","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.phrs.2020.105050_bib0470","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/icb.1996.81","article-title":"Cloning of the mucosal addressin MAdCAM-1 from human brain: identification of novel alternatively spliced transcripts","volume":"74","author":"Leung","year":"1996","journal-title":"Immunol. Cell Biol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105050_bib0475","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/ecco-jcc\/jjx128","article-title":"Effect of PF-00547659 on central nervous system immune surveillance and circulating \u03b27+ T cells in Crohn\u2019s disease: report of the TOSCA Study","volume":"12","author":"D\u2019Haens","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"1","key":"10.1016\/j.phrs.2020.105050_bib0480","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/ecco-jcc\/jjx121","article-title":"Anti-MAdCAM antibody increases \u00df7+ t cells and CCR9 gene expression in the peripheral blood of patients with Crohn\u2019s disease","volume":"12","author":"Hassan-Zahraee","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"6","key":"10.1016\/j.phrs.2020.105050_bib0485","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/ecco-jcc\/jjy217","article-title":"Molecular profiling of ulcerative colitis subjects from the TURANDOT trial reveals novel pharmacodynamic\/efficacy biomarkers","volume":"13","author":"Zhou","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"6","key":"10.1016\/j.phrs.2020.105050_bib0490","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1053\/gast.2001.24015","article-title":"Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn\u2019s disease","volume":"120","author":"Schreiber","year":"2001","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.phrs.2020.105050_bib0495","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1365-2036.2006.02910.x","article-title":"A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis","volume":"23","author":"van Deventer","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"14","key":"10.1016\/j.phrs.2020.105050_bib0500","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2217\/imt-2017-0085","article-title":"Alicaforsen in the treatment of pouchitis","volume":"9","author":"Greuter","year":"2017","journal-title":"Immunotherapy"},{"issue":"6","key":"10.1016\/j.phrs.2020.105050_bib0505","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1007\/s10620-010-1525-6","article-title":"Efalizumab, a human monoclonal anti-CD11a antibody, in the treatment of moderate to severe Crohn\u2019s Disease: an open-label pilot study","volume":"56","author":"James","year":"2011","journal-title":"Dig. Dis. Sci."},{"issue":"Suppl._1","key":"10.1016\/j.phrs.2020.105050_bib0510","first-page":"S285","article-title":"P372. A multicentre, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of the S1P receptor modulator KRP203 in subjects with moderately active refractory ulcerative colitis*","volume":"10","author":"Radeke","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"18","key":"10.1016\/j.phrs.2020.105050_bib0515","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105050_bib0520","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.14309\/00000434-201710001-00595","article-title":"Safety and efficacy of long-term treatment with ozanimod: an oral S1P receptor modulator, in moderate to severe ulcerative colitis - TOUCHSTONE extension 2-year follow-up: 595","volume":"112","author":"Sandborn","year":"2017","journal-title":"Am. J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.phrs.2020.105050_bib0525","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2020.105050_bib0530","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jcph.887","article-title":"Results from the first-in-Human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator","volume":"57","author":"Tran","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"Supplement_1","key":"10.1016\/j.phrs.2020.105050_bib0535","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1093\/ecco-jcc\/jjx180.700","article-title":"P573 Safety and immune modulatory properties of etrasimod (APD334), a next-generation oral, selective sphingosine 1-phosphate receptor (S1PR) modulator, in healthy volunteers","volume":"12","author":"Peyrin-Biroulet","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"3","key":"10.1016\/j.phrs.2020.105050_bib0540","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.phrs.2020.105050_bib0545","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1124\/jpet.118.254268","article-title":"The selective sphingosine 1-Phosphate receptor modulator etrasimod regulates lymphocyte trafficking and alleviates experimental colitis","volume":"369","author":"Al-Shamma","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2020.105050_bib0550","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume":"16","author":"Peyrin-Biroulet","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.phrs.2020.105050_bib0555","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/bcp.13203","article-title":"Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects","volume":"83","author":"Harada","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.phrs.2020.105050_bib0560","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226154","article-title":"Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells","volume":"14","author":"Shimano","year":"2019","journal-title":"PLoS One"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182031358X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182031358X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:23:38Z","timestamp":1760912618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366182031358X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":112,"alternative-id":["S104366182031358X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105050","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controlling leukocyte trafficking in IBD","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105050"}}